Hottest Stories on Wall Street: Ultra Clean Holdings (NASDAQ:UCTT), Synergy Pharmaceuticals (NASDAQ:SGYP), Benefitfocus (NASDAQ:BNFT)

BBCN Bancorp, Inc. (NASDAQ:BBCN) shares moved up 0.58% in last trading session and ended the day at $15.53. BBCN has a return on assets of 1.30%. BBCN Bancorp, Inc. (NASDAQ:BBCN) quarterly performance is 1.24%.

BBCN Bancorp, Inc. (NASDAQ:BBCN) announced that the company will issue its financial results for the 2015 fourth quarter and full year after the market closes on Monday, January 25, 2016.

West Marine Inc. (NASDAQ:WMAR) ended the last trading day at $8.06. Company weekly volatility is calculated as 3.60% and price to cash ratio as 3.29. West Marine Inc. (NASDAQ:WMAR) showed a weekly performance of -3.47%.

West Marine, Inc. (NASDAQ:WMAR) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday, Market Beat Ratings reports.

On 15 January, Ultra Clean Holdings Inc. (NASDAQ:UCTT) shares fell -4.78% and was closed at $4.98. UCTT EPS growth in last 5 year was 19.20%. Ultra Clean Holdings Inc. (NASDAQ:UCTT) year to date (YTD) performance is -2.73%.

Ultra Clean Holdings Inc. (NASDAQ:UCTT) reaffirmed its fourth quarter 2015 revenue guidance. The Company expects revenue for the fourth quarter of 2015 to be at the high end of the range of $98.0 million to $103.0 million. Based on its current outlook, the Company also expects a sequential increase in revenue for the first quarter of 2016.

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) shares fell -8.82% in last trading session and ended the day at $4.03. SGYP has a return on assets of -66.80%. Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) quarterly performance is -37.71%.

On 11 January, Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) announced positive phase 1b data with its second uroguanylin analog, dolcanatide, in a double-blind, placebo-controlled, four-week study evaluating 28 patients with mild-to-moderate ulcerative colitis. Analysis of the data indicates clear signals of improvement in dolcanatide-treated patients compared with placebo-treated patients. Dolcanatide was also safe and well tolerated.

Benefitfocus, Inc. (NASDAQ:BNFT) caters to the Technology space. It has a net profit margin of -37.00% and weekly performance is -0.58%. On the last day of trading company shares ended up at $31.06. Benefitfocus, Inc. (NASDAQ:BNFT) distance from 50-day simple moving average (SMA50) is -9.27%.

Benefitfocus, Inc. (NASDAQ:BNFT) announced that they have joined the Ultimate Software UltiPro® Developer Network (UDN). The new partnership gives Benefitfocus and Ultimate Software the ability to integrate their solutions to make it easier for mutual customers to exchange data between UltiPro’s HCM solution and BENEFITFOCUS® Marketplace.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *